EP3386509A1 - Use of agonists of type-2 dopaminergic receptors in treatment of conditions caused by elevated vascular endothelial growth factor levels - Google Patents

Use of agonists of type-2 dopaminergic receptors in treatment of conditions caused by elevated vascular endothelial growth factor levels

Info

Publication number
EP3386509A1
EP3386509A1 EP16831636.2A EP16831636A EP3386509A1 EP 3386509 A1 EP3386509 A1 EP 3386509A1 EP 16831636 A EP16831636 A EP 16831636A EP 3386509 A1 EP3386509 A1 EP 3386509A1
Authority
EP
European Patent Office
Prior art keywords
cabergoline
treatment
growth factor
vascular endothelial
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP16831636.2A
Other languages
German (de)
French (fr)
Other versions
EP3386509B1 (en
Inventor
Maciej OSEKA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oseka Maciej
Original Assignee
Ofta Sp ZOO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ofta Sp ZOO filed Critical Ofta Sp ZOO
Priority to PL16831636T priority Critical patent/PL3386509T3/en
Publication of EP3386509A1 publication Critical patent/EP3386509A1/en
Application granted granted Critical
Publication of EP3386509B1 publication Critical patent/EP3386509B1/en
Priority to HRP20192256TT priority patent/HRP20192256T1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to use of type-2 dopaminergic receptor agonists in treatment of eye diseases caused by an elevated level of vascular endothelial growth factor (VEGF), particularly in treatment or prevention of retinal disorders resulting from an increase in permeability of blood vessels and their angiogenesis.
  • VEGF vascular endothelial growth factor
  • Eye diseases in which an increase in permeability of blood vessels and their angiogenesis occur, include a multitude of diseases, mainly of the retina, such as diabetic macular edema, diabetic retinopathy, age-related macular degeneration, retinal artery occlusion or retinal vein occlusion.
  • Diabetic macular edema develops in patients with prolonged diabetes and more advanced presentation of diabetic retinopathy. It occurs in about 14% of diabetics. The frequency of DME occurrence is depends on stage of retinopathy and diabetes type and duration. After 25 years of diabetes DME occurs in about 30% of patients with type 1 and type 2 diabetes treated with insulin and in about 15% of patients with type 2 diabetes treated with oral anti-diabetic medication. Diabetic macular edema is defined by a presence of liquid or hard exudates within 1 dd (disc diameter of the optic nerve) from the center of the macula.
  • Diabetic retinopathy is the most common cause of blindness in developed countries nowadays. It is the result of the increase in diabetes prevalence in those countries. According to WHO in the year 2002 diabetic retinopathy was the cause of blindness in 1 .8 million people (4.8%) worldwide. In USA, every year, it becomes the reason for the loss of vision for about 12-24 thousands of patients suffering from diabetes. From a clinical point of view DR has few variants, such as non-proliferative retinopathy, pre-proliferative retinopathy, diabetic maculopathy, proliferative retinopathy and advanced diabetic retinopathy. In most of these cases edema of the retina occurs and, in case of proliferative forms, proliferation of pathological blood vessels.
  • Age-related macular degeneration is the main reason of the loss of vision in adults over 50 years old. It occurs in 8.8% of the population, more frequently in females, and its occurrence increases with age and it affects almost 28% of people over age 75. It affects 50 million people globally. Due to population ageing the problem of AMD increases and about 10% of people over 45 years old are endangered by the disease. The so-called dry form of AMD makes up 90% of AMD cases and causes atrophic lesions within the macula and gradual loss of vision. In 10% of patients with AMD the wet (exudative) AMD form occurs, which causes blood vessel carcinogenesis in retina and choroid (choroidal neovascularization; CNV) and leads to a rapid vision worsening or vision loss.
  • CNV blood vessel carcinogenesis in retina and choroid
  • Retinal artery occlusion or its branch occlusion, is a relatively rare condition. It is characterized by a rapid and pain-less loss of vision. In case of quick treatment a complete or partial recovery of the vision is achieved.
  • One of the complications of the central retinal artery occlusion is the proliferation of pathological blood vessels in eye tissues.
  • Retinal vein occlusion occurs when central retinal vein (central retinal vein occlusion - CRVO) or its branch (branch retinal vein occlusion - BRVO) is blocked. It leads to different kinds of vision degradation.
  • CRVO and BRVO are the second most common vascular diseases of the retina. The form with ischemia is less common than the form without it.
  • Retinal vein occlusions occur with incidence of about 2 cases per 1000 people over 40 years of age and more than 5 cases per 1000 people over 64 years of age.
  • central retinal artery occlusion in case of retinal vein occlusion late complications are possible, involving carcinogenesis of pathological blood vessels in the retina and in other eye tissues e.g. in drainage angle or iris.
  • VEGF vascular endothelial growth factor
  • VEGF is a group of cytokines comprising a group of substances that include: VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F and PIGF (placental growth factor).
  • the VEGF cytokines act through specific receptors. Currently a few of types thereof are known such as: VEGFR-1 , VEGFR-2, FLK-1 and VEGFR-3.
  • VEGF binds with receptors, which triggers a cascade of chemical reactions, which finally lead to an increase in permeability of blood vessels and stimulation of proliferation and migration of epithelial cells of blood and lymphatic vessels. Migrating cells of the endothelium create tubular structures, which are the buds of new blood vessels.
  • VEGF vascular endothelial growth factor
  • pro-inflammatory cytokines such as interleukin 1 (IL-1 ) and interleukin 6 (IL-6), substances secreted by tissues during the course of hypoxia e. g. hypoxia-induced factor (HIF-1 ), other growth factors e. g. transforming growth factor (TGF), insulin-like growth factor (IGF), fibroblast growth factor (FGF) and platelet-derived growth factor (PDGF).
  • IL-1 interleukin 1
  • IL-6 interleukin 6
  • TGF transforming growth factor
  • IGF insulin-like growth factor
  • FGF fibroblast growth factor
  • PDGF platelet-derived growth factor
  • angiogenesis in eye tissues occurs mostly in low-oxygen supply conditions due to e. g. a decrease in blood flow or an increase in tissue demand for oxygen and in chronic tissue inflammation, when factors promoting secretion of VEGF are released.
  • the blood vessels that are created in that way are responsible for the occurrence, inter alia, of collateral circulation in cardiac muscle, which plays a very important role in supporting correct tissue oxidation.
  • VEGF vascular endothelial growth factor
  • VEGF also stimulates formation of new vessels, which are characterized by high permeability, which further increases edema of surrounding tissues.
  • Newly created blood vessels disturb the physiological layout and course of blood vessels in the retina and the choroid of the eye and grow into vessel-free spaces e. g. the vitreous body.
  • the walls of blood vessels formed during angiogenesis are fragile, they often break and cause hemorrhages into the vitreous body.
  • VEGF vascular endothelial growth factor
  • VEGF vascular endothelial growth factor
  • the present invention relates to a use of type2 dopaminergic receptor agonists such as cabergoline in treatment of eye diseases caused by an elevated level of VEGF in eye tissues, which leads to their edema and to formation of pathological blood vessels.
  • the invention thus relates to a use of cabergoline and other agonists of a dopaminergic D2 receptor in treatment of eye diseases caused by an elevated level of vascular endothelial growth factor.
  • the present invention also relates to a possibility of using cabergoline and other agonists of a dopaminergic D2 receptor in treatment of eye diseases caused by an elevated level of vascular endothelial growth factor, in particular of diseases of an eye retina caused by an increase in permeability of blood vessels and/or their angiogenesis.
  • the invention also relates to a pharmaceutical composition containing as an active ingredient cabergoline or other agonists of a dopaminergic D2 receptor for use in treatment of eye diseases caused by an elevated level of vascular endothelial growth factor, in particular diseases of an eye retina caused by an increase in permeability of blood vessels and/or their carcinogenesis.
  • the composition according to the invention is for oral administration.
  • OHSS ovarian hyperstimulation syndrome
  • Cabergoline having a structure according to the formula shown below, is a dopaminergic D2 receptor agonist.
  • Cabergoline is used in treatment of disorders related to an excessive prolactin secretion (e. g. menstrual disorders, lack of ovulation, galactorrhea), pituitary adenoma, idiopathic hyperprolactinemia, empty sella syndrome.
  • Cabergoline is used in treatment of the above mentioned disorders in doses from 0.5 mg once per day or from 0.25 mg to 4.5 mg once per week.
  • Cabergoline is successfully used in prevention and treatment of OHSS as well, with a daily dose of 0.5 mg - 1 mg over 7-14 days since the stimulation of ovulation.
  • Polish patent application P.343593 relates to use of cabergoline in treatment of a restless legs syndrome, while in polish patent applications P.344574, P.380898 and P.383475 use of cabergoline in combination with pramipexole for treatment of multiple systems atrophy, progressive supranuclear palsy and Parkinson's disease were described.
  • the rats were injected intraperitoneally with streptozocin at a dose of 60 mg/kg b.w. After 30 days since administration of streptozocin blood glucose level was checked and only rats with the blood glucose levels of over 250 mg% were qualified for the experiment.
  • the following parameters were assessed: permeability of blood-retinal barrier using the dextran method (BRB) and the thickness of the retina using optical coherence tomography (OCT).
  • the research was conducted on an experimental model of Wistar strain rats. Central retinal vein occlusion was performed using a 532 nm laser.
  • CNV choroidal neovascularization
  • CNV Choroidal neovascularization

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a use of type-2 dopaminergic receptor agonists in treatment of eye diseases caused by an elevated level of vascular endothelial growth factor (VEGF), particularly in treatment or prevention of diseases of an eye retina resulting from an increase in permeability of blood vessels and their angiogenesis using cabergoline, a dopaminergic D2 receptor agonist.

Description

Use of agonists of type-2 dopaminergic receptors in treatment of conditions caused by elevated vascular endothelial growth factor levels
The present invention relates to use of type-2 dopaminergic receptor agonists in treatment of eye diseases caused by an elevated level of vascular endothelial growth factor (VEGF), particularly in treatment or prevention of retinal disorders resulting from an increase in permeability of blood vessels and their angiogenesis.
Eye diseases, in which an increase in permeability of blood vessels and their angiogenesis occur, include a multitude of diseases, mainly of the retina, such as diabetic macular edema, diabetic retinopathy, age-related macular degeneration, retinal artery occlusion or retinal vein occlusion.
Diabetic macular edema (DME) develops in patients with prolonged diabetes and more advanced presentation of diabetic retinopathy. It occurs in about 14% of diabetics. The frequency of DME occurrence is depends on stage of retinopathy and diabetes type and duration. After 25 years of diabetes DME occurs in about 30% of patients with type 1 and type 2 diabetes treated with insulin and in about 15% of patients with type 2 diabetes treated with oral anti-diabetic medication. Diabetic macular edema is defined by a presence of liquid or hard exudates within 1 dd (disc diameter of the optic nerve) from the center of the macula.
Diabetic retinopathy (DR) is the most common cause of blindness in developed countries nowadays. It is the result of the increase in diabetes prevalence in those countries. According to WHO in the year 2002 diabetic retinopathy was the cause of blindness in 1 .8 million people (4.8%) worldwide. In USA, every year, it becomes the reason for the loss of vision for about 12-24 thousands of patients suffering from diabetes. From a clinical point of view DR has few variants, such as non-proliferative retinopathy, pre-proliferative retinopathy, diabetic maculopathy, proliferative retinopathy and advanced diabetic retinopathy. In most of these cases edema of the retina occurs and, in case of proliferative forms, proliferation of pathological blood vessels.
Age-related macular degeneration (AMD) is the main reason of the loss of vision in adults over 50 years old. It occurs in 8.8% of the population, more frequently in females, and its occurrence increases with age and it affects almost 28% of people over age 75. It affects 50 million people globally. Due to population ageing the problem of AMD increases and about 10% of people over 45 years old are endangered by the disease. The so-called dry form of AMD makes up 90% of AMD cases and causes atrophic lesions within the macula and gradual loss of vision. In 10% of patients with AMD the wet (exudative) AMD form occurs, which causes blood vessel carcinogenesis in retina and choroid (choroidal neovascularization; CNV) and leads to a rapid vision worsening or vision loss.
Retinal artery occlusion, or its branch occlusion, is a relatively rare condition. It is characterized by a rapid and pain-less loss of vision. In case of quick treatment a complete or partial recovery of the vision is achieved. One of the complications of the central retinal artery occlusion is the proliferation of pathological blood vessels in eye tissues.
Retinal vein occlusion occurs when central retinal vein (central retinal vein occlusion - CRVO) or its branch (branch retinal vein occlusion - BRVO) is blocked. It leads to different kinds of vision degradation. CRVO and BRVO are the second most common vascular diseases of the retina. The form with ischemia is less common than the form without it. Retinal vein occlusions occur with incidence of about 2 cases per 1000 people over 40 years of age and more than 5 cases per 1000 people over 64 years of age. As with central retinal artery occlusion in case of retinal vein occlusion late complications are possible, involving carcinogenesis of pathological blood vessels in the retina and in other eye tissues e.g. in drainage angle or iris.
Function of the vascular endothelial growth factor (VEGF) in the increase in permeability of blood vessels and angiogenesis of blood vessels.
VEGF is a group of cytokines comprising a group of substances that include: VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F and PIGF (placental growth factor). The VEGF cytokines act through specific receptors. Currently a few of types thereof are known such as: VEGFR-1 , VEGFR-2, FLK-1 and VEGFR-3. VEGF binds with receptors, which triggers a cascade of chemical reactions, which finally lead to an increase in permeability of blood vessels and stimulation of proliferation and migration of epithelial cells of blood and lymphatic vessels. Migrating cells of the endothelium create tubular structures, which are the buds of new blood vessels.
Secretion of VEGF is stimulated by many factors. These include pro-inflammatory cytokines, such as interleukin 1 (IL-1 ) and interleukin 6 (IL-6), substances secreted by tissues during the course of hypoxia e. g. hypoxia-induced factor (HIF-1 ), other growth factors e. g. transforming growth factor (TGF), insulin-like growth factor (IGF), fibroblast growth factor (FGF) and platelet-derived growth factor (PDGF).
The process of angiogenesis in eye tissues occurs mostly in low-oxygen supply conditions due to e. g. a decrease in blood flow or an increase in tissue demand for oxygen and in chronic tissue inflammation, when factors promoting secretion of VEGF are released. The blood vessels that are created in that way are responsible for the occurrence, inter alia, of collateral circulation in cardiac muscle, which plays a very important role in supporting correct tissue oxidation.
Unfortunately, newly created blood vessels are not always beneficial for functioning of organs. For example, in the case of eye tissues, there occurs a pathological growth of blood vessels and breakdown of blood-retinal barrier, which in normal conditions prevents excessive penetration of fluid from blood vessels to tissues.
Function of the vascular endothelial growth factor (VEGF) in the increase in permeability of blood vessels and angiogenesis of blood vessels in eye tissues. An increase in secretion of VEGF occurs in diabetic retinopathy (proliferative and pre- proliferative), wet age-related macular degeneration, central retinal artery occlusion, central (or branch) retinal vein occlusion. The released VEGF increases permeability of blood vessels, which leads to breakdown of blood-retinal barrier, increase of in penetration of fluid to the retina and edema thereof. An increase in intra-tissue pressure in the retina causes breakdown of tissue and atrophy thereof. VEGF also stimulates formation of new vessels, which are characterized by high permeability, which further increases edema of surrounding tissues. Newly created blood vessels disturb the physiological layout and course of blood vessels in the retina and the choroid of the eye and grow into vessel-free spaces e. g. the vitreous body. The walls of blood vessels formed during angiogenesis are fragile, they often break and cause hemorrhages into the vitreous body.
Currently, in order to decrease the edema of eye tissues and to inhibit angiogenesis inhibitors of VEGF or its receptors are used, such as ranibizumab (recombinant humanized monoclonal antibody fragment against VEGF-A), bevacizumab (recombinant humanized monoclonal antibody against VEGF-A) and aflibercept (Fc fragment of a receptor for VEGF). They are administered as repeated intravitreal injections, usually with one or two month intervals. The injection form of administration of the VEGF inhibitors requires sterile administration conditions, limits the number of potential patients and has a high risk of side effects. Therefore, there is still a need for development of new means for treatment of eye diseases caused by an elevated level of vascular endothelial growth factor (VEGF), which would be effective and easily-available and their way of administration would be easier.
In order to find the solution for this problem the inventor of the present invention has conducted extensive research and has unexpectedly found that agonists of the type-2 dopaminergic receptors may be useful in treatment of eye diseases caused by an elevated level of vascular endothelial growth factor (VEGF), particularly in treatment or prevention of diseases of eye tissues, resulting from an increase in permeability of blood vessels and their carcinogenesis. Additionally the inventor has found that the most preferred agonist of a dopaminergic D2 receptor is cabergoline.
Thus, the present invention relates to a use of type2 dopaminergic receptor agonists such as cabergoline in treatment of eye diseases caused by an elevated level of VEGF in eye tissues, which leads to their edema and to formation of pathological blood vessels.
The invention thus relates to a use of cabergoline and other agonists of a dopaminergic D2 receptor in treatment of eye diseases caused by an elevated level of vascular endothelial growth factor.
The present invention also relates to a possibility of using cabergoline and other agonists of a dopaminergic D2 receptor in treatment of eye diseases caused by an elevated level of vascular endothelial growth factor, in particular of diseases of an eye retina caused by an increase in permeability of blood vessels and/or their angiogenesis.
The invention also relates to a pharmaceutical composition containing as an active ingredient cabergoline or other agonists of a dopaminergic D2 receptor for use in treatment of eye diseases caused by an elevated level of vascular endothelial growth factor, in particular diseases of an eye retina caused by an increase in permeability of blood vessels and/or their carcinogenesis.
Preferably, the composition according to the invention is for oral administration.
Function of dopaminergic D2 receptors in inhibition of VEGF effects.
It has been shown in experimental research that dopamine acting through dopamine D2 receptors inhibits permeability of blood vessels and proliferation and migration of vascular endothelial cells. This activity is presumably achieved by decreasing the number of VEGF-2 receptors and a decrease in affinity of VEGF-2 receptors to VEGF. The above observations are supported by clinical data. The agonist of dopaminergic D2 receptors- cabergoline is successfully used in prevention and treatment of ovarian hyperstimulation syndrome (OHSS). OHSS is related to an increased VEGF secretion by granulosa cells of an ovarian follicle due to hormonal stimulation of ovulation and to an increase in blood vessel permeability resulting from activation of the VEGF-2 receptor.
Pharmacological effects of dopaminergic D2 receptor agonist - cabergoline.
Cabergoline, having a structure according to the formula shown below, is a dopaminergic D2 receptor agonist.
Cabergoline is used in treatment of disorders related to an excessive prolactin secretion (e. g. menstrual disorders, lack of ovulation, galactorrhea), pituitary adenoma, idiopathic hyperprolactinemia, empty sella syndrome. Cabergoline is used in treatment of the above mentioned disorders in doses from 0.5 mg once per day or from 0.25 mg to 4.5 mg once per week. Cabergoline is successfully used in prevention and treatment of OHSS as well, with a daily dose of 0.5 mg - 1 mg over 7-14 days since the stimulation of ovulation.
Polish patent application P.343593 relates to use of cabergoline in treatment of a restless legs syndrome, while in polish patent applications P.344574, P.380898 and P.383475 use of cabergoline in combination with pramipexole for treatment of multiple systems atrophy, progressive supranuclear palsy and Parkinson's disease were described.
Example 1
The effects of administration of cabergoline on permeability of blood-retinal barrier and on retinal thickness in an experimental model for diabetic retinopathy
The research was conducted on an experimental model of Wistar strain rats. In order to cause diabetes the rats were injected intraperitoneally with streptozocin at a dose of 60 mg/kg b.w. After 30 days since administration of streptozocin blood glucose level was checked and only rats with the blood glucose levels of over 250 mg% were qualified for the experiment. In the course of the experiment, the following parameters were assessed: permeability of blood-retinal barrier using the dextran method (BRB) and the thickness of the retina using optical coherence tomography (OCT).
In the experiment, 4 experimental groups were compared: healthy animals without cabergoline administration, healthy animals with cabergoline administration (14 days of use), animals with diabetes without cabergoline, animals with diabetes with cabergoline (14 days of use). Cabergoline was administered to the animals in oral form at a dose of 0.05 mg/kg b.w. over 14 days.
Example 2
The effects of administration of cabergoline on permeability of blood-retinal barrier and retinal thickness in an experimental model for central retinal vein occlusion.
The research was conducted on an experimental model of Wistar strain rats. Central retinal vein occlusion was performed using a 532 nm laser.
In the course of the experiment, the following parameters were assessed: permeability of blood-retinal barrier using the dextran method (BRB) and the thickness of the retina using optical coherence tomography (OCT).
In the experiment, 4 experimental groups were compared: healthy animals without cabergoline administration, healthy animals with cabergoline administration (14 days of use), animals with central retinal vein occlusion without cabergoline, animals with central retinal vein occlusion with cabergoline (14 days of use). Cabergoline was administered to the animals in oral form at a dose of 0.05 mg/kg b.w. over 14 days. Experimental group/Parameter BRB (μΙ/g/min) OCT (μηι)
Control group 23.2±6.8 235±14
Group with central retinal vein occlusion 48.9±14.6 419±36 without cabergoline
Healthy group with cabergoline 25.1 ±4.2 258±13
Group with central retinal vein occlusion 33.3±12.9 343±28 with cabergoline
Example 3
The effects of administration of cabergoline on permeability of blood-retinal barrier and retinal thickness in an experimental model for choroidal neovascularization (CNV).
The research was conducted on an experimental model of Wistar strain rats. Choroidal neovascularization (CNV) was performed by photocoagulation of the retina using a 532 nm laser.
In the course of the experiment, the following parameters were assessed: permeability of blood-retinal barrier using the dextran method (BRB) and the thickness of the retina using optical coherence tomography (OCT).
In the experiment, 4 experimental groups were compared: healthy animals without cabergoline administration, healthy animals with cabergoline administration (14 days of use), animals with CNV without cabergoline, animals with CNV with cabergoline (14 days of use). Cabergoline was administered to the animals in oral form at a dose of 0,05 mg/kg b.w. over 14 days.
Experimental group/Parameter BRB (μΙ/g/min) OCT ( m)
Control group 27.3±9.2 242±28
Group with CNV without cabergoline 43.1 ±9.9 362±32
Healthy group with cabergoline 28.5±6.6 221 ±22
Group with CNV with cabergoline 37.4±15.2 283±17

Claims

Claims
1 . Use of type-2 dopaminergic receptor agonists in treatment of eye diseases caused by an elevated level of vascular endothelial growth factor.
2. The use according to claim 1 , wherein the eye disease is a disease of an eye retina caused by an increase in permeability of blood vessels and/or their angiogenesis.
3. The use according to claim 1 or 2, wherein the type-2 dopaminergic receptor agonist is cabergoline.
4. Use of cabergoline in treatment of eye diseases caused by an elevated level of vascular endothelial growth factor.
5. Cabergoline for use in treatment of eye diseases caused by an elevated level of vascular endothelial growth factor.
6. Cabergoline for use according to claim 5, wherein the eye disease is a disease of an eye retina caused by an increase in permeability of blood vessels and/or their angiogenesis.
7. A pharmaceutical composition comprising cabergoline as an active ingredient for use in treatment of eye diseases caused by an elevated level of vascular endothelial growth factor.
8. The composition according to claim 7, for use, wherein the eye disease is a disease of an eye retina caused by an increase in permeability of blood vessels and/or their angiogenesis.
9. The composition according to claim 7 or 8 for oral administration.
EP16831636.2A 2015-12-09 2016-12-09 Use of cabergoline in the treatment of eye diseases caused by elevated vascular endothelial growth factor levels Active EP3386509B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL16831636T PL3386509T3 (en) 2015-12-09 2016-12-09 Use of cabergoline in the treatment of eye diseases caused by elevated vascular endothelial growth factor levels
HRP20192256TT HRP20192256T1 (en) 2015-12-09 2019-12-16 Use of cabergoline in the treatment of eye diseases caused by elevated vascular endothelial growth factor levels

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL415170A PL232974B1 (en) 2015-12-09 2015-12-09 Application of the dopaminergic receptors type 2 agonists in treatment of eye chronic diseases caused by the increased level of endothelium derivative cell growth factor
PCT/IB2016/057483 WO2017098461A1 (en) 2015-12-09 2016-12-09 Use of agonists of type-2 dopaminergic receptors in treatment of conditions caused by elevated vascular endothelial growth factor levels

Publications (2)

Publication Number Publication Date
EP3386509A1 true EP3386509A1 (en) 2018-10-17
EP3386509B1 EP3386509B1 (en) 2019-09-18

Family

ID=57909808

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16831636.2A Active EP3386509B1 (en) 2015-12-09 2016-12-09 Use of cabergoline in the treatment of eye diseases caused by elevated vascular endothelial growth factor levels

Country Status (13)

Country Link
US (2) US20180360820A1 (en)
EP (1) EP3386509B1 (en)
CN (1) CN108472294B (en)
CA (1) CA3007953C (en)
DK (1) DK3386509T3 (en)
ES (1) ES2761875T3 (en)
HR (1) HRP20192256T1 (en)
IL (1) IL259903B (en)
LT (1) LT3386509T (en)
PL (2) PL232974B1 (en)
PT (1) PT3386509T (en)
RU (1) RU2698728C1 (en)
WO (1) WO2017098461A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL241086B1 (en) * 2017-09-26 2022-08-01 Oseka Maciej Pergolide to be applied in treatment of eye diseases connected with increased level of vascular endothelial growth factor (VEGF) and the pergolid-containing pharmaceutical composition
PL430675A1 (en) * 2019-07-23 2021-01-25 Osęka Maciej Bromocriptine for the treatment of ocular diseases related to elevated levels of vascular endothelial growth factor (VEGF) and a pharmaceutical composition containing bromocriptine
CN113082031A (en) * 2021-03-09 2021-07-09 温州医科大学附属眼视光医院 Application of dopamine D1 and D2 receptor nonselective agonist in preparation of drugs for treating pathological angiogenesis of eyes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526892A (en) * 1981-03-03 1985-07-02 Farmitalia Carlo Erba, S.P.A. Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
US6114326A (en) * 1998-03-27 2000-09-05 Pharmacia & Upjohn Company Use of cabergoline in the treatment of restless legs syndrome
EA200300124A1 (en) * 1998-05-15 2003-10-30 Фармация Энд Апджон Компани APPLICATION OF PRAMIPEXOL FOR THE TREATMENT OF POLYSYSTEM ATROPHY AND PROGRESSIVE SUPRANUKLEAR PARALICH
US20070155770A1 (en) * 2006-01-03 2007-07-05 Cedars-Sinai Medical Center Treatment of anoragasmia or delayed orgasm
KR100923195B1 (en) * 2006-04-04 2009-10-22 고려대학교 산학협력단 Methods for modulating the development of dopamine neuron by the Dopamine D2 receptor and compositions thereof
ATE535243T1 (en) * 2007-05-11 2011-12-15 Santen Pharmaceutical Co Ltd PROPHYLACTIC OR THERAPEUTIC AGENT FOR POSTERIOR EYE DISEASE HAVING SELECTIVE NON-ERGOT-D2 RECEPTOR AGONIST AS THE ACTIVE INGREDIENT
CN102791134B (en) * 2009-12-04 2015-04-22 魄金莱默有限公司 Method of using dopamine reuptake inhibitors and their analogs for treating diabetes symptoms and delaying or preventing diabetes-associated pathologic conditions

Also Published As

Publication number Publication date
PL3386509T3 (en) 2020-08-24
CN108472294A (en) 2018-08-31
RU2698728C1 (en) 2019-08-29
US11324740B2 (en) 2022-05-10
US20200222387A1 (en) 2020-07-16
ES2761875T3 (en) 2020-05-21
PT3386509T (en) 2019-12-30
WO2017098461A1 (en) 2017-06-15
CA3007953C (en) 2022-11-29
PL415170A1 (en) 2017-06-19
US20180360820A1 (en) 2018-12-20
LT3386509T (en) 2020-01-27
IL259903B (en) 2020-09-30
PL232974B1 (en) 2019-08-30
EP3386509B1 (en) 2019-09-18
DK3386509T3 (en) 2019-12-16
IL259903A (en) 2018-07-31
HRP20192256T1 (en) 2020-03-06
CN108472294B (en) 2021-07-13
CA3007953A1 (en) 2017-06-15

Similar Documents

Publication Publication Date Title
US11324740B2 (en) Use of agonists of type-2 dopaminergic receptors in treatment of conditions caused by elevated vascular endothelial growth factor levels
Pożarowska et al. The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy
Barros et al. The effects of the subconjunctival injection of bevacizumab (Avastin®) on angiogenesis in the rat cornea
RU2519739C2 (en) Ophthalmological pharmaceutical compositions for neoangiogenic eye pathologies
JP6944958B2 (en) Use of sirolimus for the treatment of exudative age-related macular degeneration with persistent edema
Algvere et al. Visual improvement in central retinal vein occlusion (CRVO) following intravitreal injections of bevacizumab (Avastin®)
US20170224815A1 (en) Method of Preventing and Treating Retinal Microvasculature Inflammation Using C-Met Signaling Pathway Inhibition
Abdullaev et al. APPROACHES TO THE TREATMENT OF DIABETIC RETINOPATHY
WO2021068962A1 (en) Polypeptide for diseases related to angiogenesis and lymphangiogenesis and use thereof
CN110327350B (en) Application of dopamine D1 receptor antagonist SCH39166 in preparation of drugs for treating pathological angiogenesis of eyes
Jiang et al. The efficacy and safety of intravitreal conbercept combined with mitomycin C augmented trabeculectomy for treating neovascular glaucoma
Elsayed Comparisons of Ranibizumab Injection and Dexamethasone Implant in Macular Oedema Secondary to Central Retinal Vein Occlusion
AlZamil et al. Efficacy and Safety of Primary Intravitreal 2 mg Aflibercept for Cystoid Macular Edema after Phacoemulsification
SHARM et al. Clinical Utilisation of Bevacizumab and Patient Monitoring in Retinal Vein Occlusion and Diabetic Macular Edema
WO2021014372A1 (en) Bromocriptine for use in treating eye diseases associated with elevated level of vegf and a pharmaceutical composition comprising bromocriptine
KALDIRIM et al. Intravitreal Dexamethasone Implant in the Treatment of Pseudophakic Cystoid Macular Edema or Irvine-Gass Syndrome
Vangipuram et al. Future Direction in Diabetic Eye Disease
US20200289480A1 (en) Pergolide for use in the treatment of eye diseases associated with an elevated level of vascular endothelial growth factor (vegf) and pharmaceutical composition containing pergolide
Frank Clinical Applications of Angiogenesis Research
Frank Diabetic Retinopathy: Clinical Applications of Angiogenesis Research
WO2019231800A1 (en) Anti-cgrp antibodies for treating menstrual-related migraines
Pacella et al. Adverse events associated with intraocular injection of anti-VEGF (bevacizumab) in retinal vein ccclusion: a case report
Monica-Blanka et al. Bevacizumab for Macular Edema in Branch and Central Retinal Vein Occlusion.
A AL-Laftah RANIBIZUMAB MONOTHERAPY VERSUS COMBINED RANIBIZUMAB PLUS TRIAMCINOLONE FOR TREATING DIABETIC MACULAR EDEMA; EVALUATION AFTER SINGLE INJECTION
Smith et al. The Use of Somatostatin Analogues in Diabetic Retinopathy

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180709

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20190327

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: OSEKA, MACIEJ

RIN1 Information on inventor provided before grant (corrected)

Inventor name: OSEKA, MACIEJ

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602016021056

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1180488

Country of ref document: AT

Kind code of ref document: T

Effective date: 20191015

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: REUTELER AND CIE S.A., CH

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20191211

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20192256T

Country of ref document: HR

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 3386509

Country of ref document: PT

Date of ref document: 20191230

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20191217

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20190918

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20192256T

Country of ref document: HR

Payment date: 20191216

Year of fee payment: 4

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190918

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190918

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20192256

Country of ref document: HR

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E018527

Country of ref document: EE

Effective date: 20191212

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20190403882

Country of ref document: GR

Effective date: 20200318

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190918

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 33380

Country of ref document: SK

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2761875

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20200521

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190918

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200224

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602016021056

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG2D Information on lapse in contracting state deleted

Ref country code: IS

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200119

26N No opposition filed

Effective date: 20200619

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190918

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190918

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191209

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20192256

Country of ref document: HR

Payment date: 20201125

Year of fee payment: 5

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190918

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20161209

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190918

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20192256

Country of ref document: HR

Payment date: 20211202

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20211201

Year of fee payment: 6

Ref country code: HR

Payment date: 20211202

Year of fee payment: 6

Ref country code: LT

Payment date: 20211202

Year of fee payment: 6

Ref country code: EE

Payment date: 20211202

Year of fee payment: 6

Ref country code: FI

Payment date: 20211223

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LV

Payment date: 20211202

Year of fee payment: 6

Ref country code: CH

Payment date: 20211216

Year of fee payment: 6

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190918

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1180488

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190918

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NO

Payment date: 20221205

Year of fee payment: 7

REG Reference to a national code

Ref country code: HR

Ref legal event code: PBON

Ref document number: P20192256

Country of ref document: HR

Effective date: 20221209

REG Reference to a national code

Ref country code: LT

Ref legal event code: MM4D

Effective date: 20221209

REG Reference to a national code

Ref country code: EE

Ref legal event code: MM4A

Ref document number: E018527

Country of ref document: EE

Effective date: 20221231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221209

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221231

Ref country code: EE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221231

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221209

Ref country code: HR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221209

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SK

Payment date: 20231205

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20231229

Year of fee payment: 8

Ref country code: GB

Payment date: 20231203

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20231203

Year of fee payment: 8

Ref country code: PT

Payment date: 20231207

Year of fee payment: 8

Ref country code: NL

Payment date: 20231204

Year of fee payment: 8

Ref country code: IT

Payment date: 20231227

Year of fee payment: 8

Ref country code: IE

Payment date: 20231205

Year of fee payment: 8

Ref country code: FR

Payment date: 20231203

Year of fee payment: 8

Ref country code: DK

Payment date: 20231206

Year of fee payment: 8

Ref country code: DE

Payment date: 20231206

Year of fee payment: 8

Ref country code: CZ

Payment date: 20231205

Year of fee payment: 8

Ref country code: AT

Payment date: 20231214

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20231204

Year of fee payment: 8

Ref country code: BE

Payment date: 20231204

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240108

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221209